entertainment -WSS

entertainment

author：leisure time 2025-10-02 09:21:57 - browse：2

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Chris Christie meets with Zelenskyy during Ukraine trip

hotspot

WSS

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

A controversial new treatment promises to make little people taller

entertainment

entertainment

knowledge

Guidelines to prevent youth baseball injuries need more muscle

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Medicare details structure of new drug price negotiation program

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

After affirmative action ruling, medical educators look to 'holistic review'

Pharma showers House GOP doctor with campaign cash

Duchenne breakthrough therapy leaves behind pioneering families

The PBM ad wars are taking over Washington, D.C.

Activists slam private health insurers over coverage restrictions

North Korean leader's powerful sister says warplanes repelled US spy plane

hotspot

Group behind ProMed defends move to subscription

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Physicians aren't 'burning out.' They're suffering from moral injury

UPS workers' union leader explains what's at stake as strike edges closer

Flint parents haunted by uncertainty, fears of lead poisoning

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

leisure time

entertainment

hotspot

focus